Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
D000818:Animals; D003561:Cytarabine / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D011034:Podophyllotoxin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011714:Pyrans / Q000009:adverse effects; D013713:Teniposide / Q000627:therapeutic use*
D011714:Pyrans; D003561:Cytarabine; D005047:Etoposide; D013713:Teniposide; D011034:Podophyllotoxin